Proteomics: applications and opportunities in preclinical drug development.
Advances in DNA sequencing and the near-term availability of whole genome sequences for several pharmaceutically relevant organisms promise to dramatically alter the breadth and scale of high-throughput proteomic studies. The substantial amount of literature is available in the public domain, demonstrate the potential of proteomics in the preclinical phases of pharmaceutical development. Over the next few years, it is anticipated that functional genomics and proteomics will have major impacts on the clinical phases of drug development. Expected benefits are earlier proof-of-concept studies in man and increased efficiency of clinical trials through the availability of biologically relevant markers for drug efficacy and safety.
Steiner
S
S
Large Scale Proteomics Corporation, Rockville, MD 20850, USA. sandra.steiner@lsbc.com
Witzmann
F A
FA
D015195:Drug Design; D020543:Proteome
D020543:Proteome